background pattern

Therapeutic Pipeline

For more than 30 years, we have invested in advancing the science underlying our computational platform. As our technology advanced, our company evolved along with it.

Recognizing the opportunity to leverage the full power of our platform to drive internal discovery of molecules and clinical candidates for unmet medical needs, we formed Schrödinger’s therapeutics group.

Therapeutic Pipeline
Dark Background

Proprietary Pipeline

Discovery
Preclinical
Phase 1
SGR-1505 (MALT1)

Hematologic Malignancies

DiscoveryPreclinicalPhase 1
SGR-1505 is a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor.

MALT1 is a key mediator of the NF-κB signaling pathway and the main driver of a subset of B-cell lymphomas. Ongoing, external clinical studies are showing promise of MALT1 as a potential therapeutic target for the treatment of several non-Hodgkin’s B-cell lymphomas.

SGR-1505 (MALT1)
SGR-2921 (CDC7)

AML/MDS

DiscoveryPreclinicalPhase 1
SGR-2921 is a cell division cycle 7-related protein kinase (CDC7) inhibitor.

CDC7 is a protein kinase that plays a critical role in cell cycle regulation and DNA replication. Elevated replication stress is a common feature of many highly proliferative cancers. External clinical studies are showing promise of CDC7 as a potential therapeutic target in oncology.

SGR-2921 (CDC7)
SGR-3515 (Wee1/Myt1)

Solid Tumors

DiscoveryPreclinicalPhase 1
SGR-3515 is a Wee1 G2 Checkpoint Kinase and Myelin Transcription Factor 1 (Wee1/Myt1) inhibitor.

Wee1 is a gatekeeper checkpoint kinase that prevents cellular progression through the cell cycle, allowing time for DNA repair before cell division takes place. Myt1 is a kinase found to be overexpressed in certain types of cancer. Concurrent loss of function of Wee1 and Myt1 confers selective vulnerability in cancer cells, a mechanism referred to as synthetic lethality. External clinical studies are showing promise of Wee1/ Myt1 inhibition as a potential therapeutic target in ovarian and uterine cancer.

SGR-3515 (Wee1/Myt1)
PRMT5-MTA

Oncology

DiscoveryPreclinicalPhase 1

PRMT5-MTA inhibition has demonstrated clinical responses in both hematologic and solid tumors with improved safety versus PRMT5 inhibitors due to a synthetic lethal targeting of cancer cells with MTAP-deletions. We have identified selective, potent PRMT5-MTA inhibitors with potential applications in solid tumors, brain metastases and primary CNS tumors.

EGFRC797S

Oncology

DiscoveryPreclinicalPhase 1

EGFR inhibitors are first-line standard of care agents for advanced non-small cell lung cancer patients with activating EGFR mutations. We have identified multiple EGFRC797S inhibitors with potential to treat patients whose disease progressed following first-line treatment, potentially achieving deeper, more durable responses through new combination regimens.

NLRP3

Immunology

DiscoveryPreclinicalPhase 1

NLRP3 is a validated target, and mutations in the NLRP3 gene are associated with a broad spectrum of inflammatory and auto-immune diseases. We have identified structurally distinct, selective, NLRP3 inhibitors with anti-inflammatory activity in preclinical models, and is continuing to optimize peripheral and brain-penetrant leads.

LRRK2

Neurology

DiscoveryPreclinicalPhase 1

LRRK2 is a large multifunctional kinase enzyme and mutations in the LRRK2 gene have been shown to be associated with the development of Parkinson’s disease. Schrödinger has generated cryo-electron microscopy structures of LRRK2 to accelerate the identification of novel LRRK2 inhibitors.

Undisclosed Programs

Multiple Areas

DiscoveryPreclinicalPhase 1

We are progressing a number of undisclosed programs in multiple therapeutic areas. All of these programs are currently in the discovery stage.

Partnered programs and collaborations

Schrödinger’s therapeutics group is working on a number of collaborative drug discovery programs. We are eligible to receive milestones as certain of these programs progress through discovery and development stages, and royalties on sales for certain approved products.

Partner
ProgramTherapeutic area
Status
Details
Ajax Therapeutics
JAK2Oncology
Discovery
ProgramTherapeutic area
JAK2Oncology
Status
Discovery
JAK2

Janus kinase 2 (JAK2) is a non-receptor tyrosine kinase that promotes excessive proliferation of red blood cells, white blood cells, or platelets. Mutations in the JAK2 gene are associated with several types of cancer. In collaboration with Ajax Therapeutics, Schrödinger is designing a JAK2 inhibitor. Schrödinger holds an equity stake in Ajax Therapeutics.

Bright Angel Therapeutics
Hsp90Antifungal
Discovery
ProgramTherapeutic area
Hsp90Antifungal
Status
Discovery
Hsp90

Heat shock protein 90 (Hsp90) is a chaperone protein that plays an essential role in many cellular processes, including cell cycle control, cell survival, and hormone signaling pathways. In collaboration with Bright Angel Therapeutics, Schrödinger is designing an Hsp90 inhibitor. Schrödinger holds an equity stake in Bright Angel Therapeutics.

Bristol Myers Squibb
SOS1Oncology
Preclinical
ProgramTherapeutic area
SOS1Oncology
Status
Preclinical
SOS1

SOS1 is involved in the activation and regulation of the KRAS gene. Oncogenic mutant KRAS stimulates the growth of several cancers, such as lung, pancreatic, and colon cancer. Inhibition of SOS1 is considered a potential therapeutic strategy for the treatment of KRAS-driven cancers. SOS1 is part of Schrödinger’s collaboration for BMS. Schrödinger led the discovery of a SOS1 inhibitor, and BMS is responsible for clinical development. Under the terms of the multi-target agreement signed in 2020, Schrödinger has received an upfront payment, preclinical milestone, and is eligible to receive development, regulatory, and sales-based milestone payments.

Bristol Myers Squibb
UndisclosedImmunology
Discovery
ProgramTherapeutic area
UndisclosedImmunology
Status
Discovery
Undisclosed

In collaboration with BMS, Schrödinger is progressing an undisclosed program in immunology.

Bristol Myers Squibb
UndisclosedNeurology
Discovery
ProgramTherapeutic area
UndisclosedNeurology
Status
Discovery
Undisclosed

In collaboration with BMS, Schrödinger is progressing an undisclosed program in neurology.

Bristol Myers Squibb
UndisclosedProtein degraders
Discovery
ProgramTherapeutic area
UndisclosedProtein degraders
Status
Discovery
Undisclosed

In collaboration with BMS, Schrödinger is progressing an undisclosed program to discover protein degraders targeting oncology, neurology, and immunology indications.

Lilly
UndisclosedImmunology
Discovery
ProgramTherapeutic area
UndisclosedImmunology
Status
Discovery
Undisclosed

In collaboration with Lilly, Schrödinger is progressing an undisclosed program in immunology. Under the terms of the agreement, Schrödinger received an upfront payment and is eligible to receive up to $425 million in discovery, development, and commercial milestone payments, as well as low single- to low double-digit royalties on net sales of any products emerging from the collaboration in all markets.

Loxo Therapeutics
UndisclosedOncology
Phase 1
ProgramTherapeutic area
UndisclosedOncology
Status
Phase 1
Undisclosed

In collaboration with Loxo Therapeutics, Schrödinger is progressing an undisclosed program in oncology currently in Phase I clinical studies.

Morphic Therapeutic
α4β7Inflammatory bowel diseases
Phase 2
ProgramTherapeutic area
α4β7Inflammatory bowel diseases
Status
Phase 2
α4β7

MORF-057 is an α4β7 integrin inhibitor.

α4β7 integrin is a well validated therapeutic target for the treatment of inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative-colitis (UC). Schrödinger and Morphic discovered MORF-057, which is currently progressing through Phase 2 studies in adults with moderate to severe UC. Schrödinger holds an equity stake in Morphic.

Morphic Therapeutic
α4β7GI indications
Discovery
ProgramTherapeutic area
α4β7GI indications
Status
Discovery
Next-Gen α4β7

In collaboration with Morphic, Schrödinger is designing a family of next-generation Next-Gen α4β7 inhibitors with enhanced properties.

Morphic Therapeutic
αvβ8Solid tumors, fibrosis
Discovery
ProgramTherapeutic area
αvβ8Solid tumors, fibrosis
Status
Discovery
αvβ8

αvβ8 integrin is known to activate selective isoforms of TGF-β and inhibit anti-tumor activity. Preclinical studies have shown that inhibitingα vβ8 can potentially drive responses in checkpoint refractory tumors. In collaboration with Morphic, Schrödinger is designing an αvβ8 inhibitor for the treatment of solid tumors and fibrosis.

Morphic Therapeutic
UndisclosedPulmonary arterial hypertension
Discovery
ProgramTherapeutic area
UndisclosedPulmonary arterial hypertension
Status
Discovery
Undisclosed

In collaboration with Morphic, Schrödinger is progressing an undisclosed program for evaluation as a potential treatment for pulmonary arterial hypertension.

Nimbus Therapeutics
ACCNASH
Phase 2
ProgramTherapeutic area
ACCNASH
Status
Phase 2
ACC

Acetyl-CoA carboxylase (ACC) is an enzyme involved in the synthesis of endogenous fatty acids and the breakdown of fatty acids at a cellular level. Schrödinger and Nimbus identified a unique series of ACC allosteric protein-protein interaction inhibitors with favorable pharmaceutical properties. Nimbus sold its ACC inhibitor program, firsocostat, to Gilead Sciences in a transaction valued at approximately $1.2 billion, and Schrödinger received a total of $46 million in cash distributions in 2016 and 2017.

Nimbus Therapeutics
HPK1Immuno-oncology
Phase 1/2
ProgramTherapeutic area
HPK1Immuno-oncology
Status
Phase 1/2
HPK1

Hematopoietic progenitor kinase 1 (HPK1) is an intracellular negative regulator of T cell proliferation and signaling and dendritic cell activation. Schrödinger and Nimbus identified an HPK1 inhibitor that is currently being evaluated for safety, tolerability, and preliminary anti-tumor activity in a Phase 1/2 clinical trial for patients with solid tumors.

Otsuka
UndisclosedCNS
Discovery
ProgramTherapeutic area
UndisclosedCNS
Status
Discovery
Undisclosed

In December 2022, Schrödinger and Otsuka initiated a collaboration to discover novel medicines against undisclosed central nervous system (CNS) targets. Schrödinger received an undisclosed upfront milestone payment and is eligible for additional milestones as the program progresses.

Sanofi
UndisclosedOncology
Discovery
ProgramTherapeutic area
UndisclosedOncology
Status
Discovery
Undisclosed

In collaboration with Sanofi, Schrödinger is progressing an undisclosed program in oncology.

Structure Therapeutics
APJRPulmonary arterial hypertension
Phase 1
ProgramTherapeutic area
APJRPulmonary arterial hypertension
Status
Phase 1
APJR

Apelin receptor (APJR) is a class A peptide binding G protein-coupled receptor that plays an important role in regulating blood pressure, cardiac output, and maintenance of fluid homeostasis. Schrödinger and Structure Therapeutics discovered an oral APJR agonist, ANPA-0073, which is currently being evaluated in a Phase 1 clinical study for the potential treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Schrödinger holds an equity stake in Structure.

Structure Therapeutics
UndisclosedUndisclosed
Discovery
ProgramTherapeutic area
UndisclosedUndisclosed
Status
Discovery
Undisclosed

In collaboration with Structure, Schrödinger is progressing an undisclosed program currently in discovery.

Structure Therapeutics
LPA1RIdiopathic pulmonary fibrosis
Preclinical
ProgramTherapeutic area
LPA1RIdiopathic pulmonary fibrosis
Status
Preclinical
LPA1R

Lysophosphatidic acid receptor 1 (LPA1R) regulates enteric nervous system function and contributes to chronic intestinal pseudo-obstruction. Increased LPA levels and activation of LPA1 have been implicated in pulmonary fibrosis. Schrödinger and Structure discovered an oral LPA1R agonist, LTSE-2578, which is currently in preclinical development for the potential treatment of idiopathic pulmonary fibrosis.

Takeda
TYK2Psoriasis
Phase 2
ProgramTherapeutic area
TYK2Psoriasis
Status
Phase 2
TYK2

TAK-279 is a non-receptor tyrosine-protein kinase (TYK2) inhibitor

TYK2 is a key mediator of cytokine signaling pathways implicated in multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, lupus, and inflammatory bowel diseases. Schrödinger and Nimbus discovered the TYK2 inhibitor TAK-279 (formerly NDI-034858), which was acquired by Takeda in 2023 and is currently being evaluated for the treatment of multiple autoimmune diseases following positive Phase 2b results in psoriasis. Schrödinger maintains an equity stake in Nimbus and received a $111.3 million cash distribution in connection with Takeda’s acquisition of TAK-279.

Takeda
UndisclosedOncology
Discovery
ProgramTherapeutic area
UndisclosedOncology
Status
Discovery
Undisclosed

In collaboration with Takeda, Schrödinger is advancing an undisclosed program in oncology. Under this multi-year, multi-target collaboration, Schrödinger conducts all drug discovery research and pharmacology activities through the development candidate stage, and Takeda has the option to acquire the program at either the lead optimization stage or development candidate stage and to develop and commercialize such product candidate from the program.

Undisclosed
UndisclosedCNS
Phase 1
ProgramTherapeutic area
UndisclosedCNS
Status
Phase 1
Undisclosed

In collaboration with an undisclosed company, Schrödinger is advancing an undisclosed CNS program, which is currently progressing through a Phase 1 clinical study.

Undisclosed
UndisclosedOncology
Phase 1
ProgramTherapeutic area
UndisclosedOncology
Status
Phase 1
Undisclosed

In collaboration with an undisclosed company, Schrödinger is advancing an undisclosed program in oncology, which is currently progressing through a Phase 1 clinical study.


Additionally, an early collaboration with Agios resulted in two FDA-approved medications, Idhifa® and Tibsovo®.

Our therapeutics team

Our therapeutics team

Our multidisciplinary team of platform experts and experienced drug development scientists are advancing proprietary programs in discovery and development.

We also collaborate on discovery projects with teams across the biopharma landscape in multiple disease areas, all with the potential to become first-in-class or best-in-class therapeutics.

Join our team